Our capabilities and experience
Read more about how we help manage complex clinical research across many therapeutic areas worldwide.
Page 6 of 6
Sickle cell disease (SCD) is an inherited disorder of the red blood cells (RBCs). Sickle cell anemia is the most common type of SCD. RBCs carry oxygen throughout the body via hemoglobin. With SCD, defective hemoglobin replaces normal hemoglobin. Over time, this causes many RBCs to become rigid and sickle-shaped and die earlier than normal RBCs, leading to a constant shortage.
Chagas disease (aka American trypanosomiasis) is a tropical parasitic disease caused by the protozoan parasite Trypanosoma cruzi that is found mostly in triatomine insects (aka “kissing bugs”) and in the Americas. Infection is life-long, with symptoms ranging from fever and headaches to enlarged internal organs.
In a study conducted at 17 sites spanning nine countries in a Zika endemic region of the Americas and Caribbean, timely staffing of contract research associates (CRAs) was enabled by the project team’s network of bilingual resources and knowledge of local hiring practices.
To equip Liberia with the ability to respond to ongoing health issues and potential outbreaks, a US government contract provided funding to train local leaders in Liberia’s clinical research infrastructure network.
The training aimed to build a solid foundation to conduct international quality clinical research.
CHIKV outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. It was found for the first time in the Americas on islands in the Caribbean in 2013 and has spread throughout most of the Americas. It has since been identified in over 60 countries in Asia, Africa, Europe and the Americas. No commercially available vaccine to prevent or medicine to treat CHIKV infection is currently available.
Building Capacity for Tuberculosis Research in China: The China TB Clinical Trials Consortium (CTCTC)
To help address the high global TB incidence and related death rate, the China TB Clinical Trials Consortium (CTCTC) was established by government and industry partners to help build clinical research capacity in China, which has a particularly high tuberculosis incidence.
Within a challenging, resource-limited setting, the project team succeeded in reaching FP/FV six weeks after arrival in Sierra Leone and 99.998% accuracy of the planned-to-execute budget.
In a Phase 3 study with a lengthy intervention for colorectal cancer, the project team reached a 70% retention rate, with steadily increasing enrollment rates, by implementing strategies to address poor patient enrollment and retention.